Literature DB >> 6734705

Comparison of the short-term effects of the loop diuretic piretanide and furosemide in patients with renal insufficiency.

C Marone, F C Reubi, W Lahn.   

Abstract

The natriuretic effect of the new loop diuretic piretanide was investigated in patients with severe renal insufficiency and was compared with that of furosemide. In the first study 4 hospitalized patients (serum creatinine 407 to 1220 mumol/l) were examined after administration of piretanide (12, 24, 48 and 96 mg to two patients, and 24, 48, 96 and 192 mg to 2 other subjects, given every third day). In the second study 6 hospitalized patients (serum creatinine 194 to 698 mumol/l) were studied after receiving orally 2 different doses of piretanide and 2 different doses of furosemide orally, given every fourth day. The mean natriuretic effect of 48 mg and 96 mg piretanide was 250 and 340% of the control value for the entire group, and 311 to 480% in the subgroup of patients with serum creatinine below 530 mumol/l. For a given dose the natriuresis was inversely correlated with renal function, and at a given serum creatinine level the natriuretic response was dose-dependent. The drug had less effect on water and potassium diuresis than on natriuresis. No significant difference in natriuretic effect was found on comparison with furosemide given in the ratio furosemide:piretanide 3.33:1. The pharmacokinetic data showed a direct correlation between the dose and the mean plasma concentration and also between urinary recovery of the drug and the measured natriuretic response.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734705     DOI: 10.1007/BF00542133

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Clinical use of furosemide.

Authors:  F C Reubi
Journal:  Ann N Y Acad Sci       Date:  1966-11-22       Impact factor: 5.691

2.  Kinetic and dynamic comparison of piretanide and furosemide.

Authors:  J R Lawrence; A F Ansari; H L Elliott; D J Sumner; G F Brunton; B Whiting; R Whitesmith
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

3.  The time course of delivery of furosemide into urine: an independent determinant of overall response.

Authors:  S Kaojarern; B Day; D C Brater
Journal:  Kidney Int       Date:  1982-07       Impact factor: 10.612

4.  Effects of piretanide, bumetanide and frusemide on electrolyte and urate excretion in normal subjects.

Authors:  C J Roberts; M Homeida; F Roberts; W Bogie
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

5.  Effects of a new diuretic (piretanide) compared with furosemide on renal diluting and concentrating mechanisms in patients with the nephrotic syndrome.

Authors:  C Marone; F C Reubi
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

6.  Dissociative effects of piretanide on proximal tubular PO4 and HCO3 transport.

Authors:  J Winaver; D B Sylk; P R Teredesai; J S Robertson; J B Puschett
Journal:  Am J Physiol       Date:  1980-01

7.  Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level.

Authors:  V Arroyo; J Bosch; R Casamitjana; J Cabrera; F Rivera; J Rodés
Journal:  Gut       Date:  1980-10       Impact factor: 23.059

8.  A single dose comparison of piretanide and bumetanide in congestive cardiac failure.

Authors:  M Homeida; C J Roberts; S L Dombey
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

9.  Activity of a new high efficiency diuretic in man: piretanide (HOE 118).

Authors:  N Pozet; A Hadj-Aissa; M Pellet; J Traeger
Journal:  Br J Clin Pharmacol       Date:  1980-06       Impact factor: 4.335

10.  Acute effect of high dose (48 mg) of piretanide in advanced renal insufficiency.

Authors:  A Hadj Aissa; N Pozet; M Labeeuw; M Pellet; J Traeger
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

View more
  3 in total

1.  Pitfalls of pharmacokinetic dosage guidelines in renal insufficiency.

Authors:  K Turnheim
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

3.  Pharmacokinetics of high doses of piretanide in moderate to severe renal failure.

Authors:  C Marone; F C Reubi; M Perisic; W Lahn
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.